Crossmark

Comparison of ezetimibe and atorvastatin versus atorvastatin alone on short-term major adverse cardiac events after percutaneous coronary intervention, a double-blind placebo-controlled randomized clinical trial

Crossref DOI link: https://doi.org/10.1186/s13063-025-08817-7

Published Online: 2025-03-28

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Farshidi, Hossein

Bijani, Badri

Sobhani, Seyed Alireza

Dastsouz, Farideh

Abbaszadeh, Shahin https://orcid.org/0000-0003-0211-3829
Funding

Funding for this research was provided by:

Hormozgan University of Medical Sciences (IR.HUMS.REC.1396.133)
License Information

Text and Data Mining valid from 2025-03-28

Version of Record valid from 2025-03-28
More Information

Article History

Received: 6 October 2024

Accepted: 17 March 2025

First Online: 28 March 2025

Declarations

:

: The study received ethics approval from the Ethics Committee of Hormozgan University of Medical Sciences (IR.HUMS.REC.1396.133). Informed consent was obtained from all individual participants included in the study.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below